Modern medicine has transformed human healthcare, yet every day, millions of dogs and cats still suffer from conditions we already know how to treat. Okava was born at the crossroads of human biotech and veterinary care to close that gap.
We are pet parents.
We are seasoned BioPharma veterans.
We bring the same life-saving innovations we trust for ourselves to the pets we call family.
We are pet parents.
We are seasoned BioPharma veterans.
We bring the same life-saving innovations we trust for ourselves to the pets we call family.
We’ve turned bold vision into measurable progress.
From validating breakthrough treatments to establishing strategic partnerships, OKAVA is an emerging leader in pet health that will have a lasting impact.
Clear regulatory approval pathway
Proven, differentiated products validated in real-world use
Strong (and growting) IP portfolio protects our innovative assets
Coveted grant validates unmet medical need and therapeutic promise
To advance pet health, we’ve led clinical studies in partnership with renowned veterinary experts from Cornell, University of Pennsylvania, UC Davis, the University of Florida, LSU, and other leading institutions.
Okava is a San Francisco-based biopharma company advancing breakthrough therapies to help pets live longer, healthier lives.
Our leadership team has guided IPOs, M&A transactions, and launched blockbuster products at companies like GlaxoSmithKline, Merck Animal Health, Alza, and Chewy bringing together deep expertise across human and veterinary medicine.
We amplify our internal capabilities by partnering with leading research organizations and expert advisors.
Chief Executive Officer
Research and Development
Regulatory Affairs
VP, CMC Supply Chain
CEO, Vivani Medical
CMC supply chain
Clinical Pharmacology
Pharmaceutical Technology
Contact us at
press@okava.com
Contact us at
investors@okava.com
Chief Executive Officer
Dr. Klotsman has over 20 years of diverse industry experience.He began his career at GlaxoSmithKline where he held numerous roles.
Prior to starting Okava, Michael ran his own consultancy where he served as C-suite advisor to privately and publicly held biotech companies. Michael was then recruited to a preeminent strategy consulting firm renowned for its expertise in strategic decision-making, risk management, and shareholder value creation.
Michael has a B.A. in Biochemistry & Molecular Biology, holds a MPH from the University of Michigan, a MBA. from Duke University, and a PhD from the University of North Carolina at Chapel Hill.
Research and Development
Dr. Anderson’s career spans over 30 years. Dr. Anderson earned his Ph.D. in Pharmacology.
He retired from GSK as the Worldwide Director of Respiratory Research and currently has appointments as a Research Associate Professor in the Department of Medicine and an Adjunct Associate Professor in the School of Pharmacy, both at the University of North Carolina, Chapel Hill.
Regulatory Affairs
He earned his VMD from the University of Pennsylvania and his JD from Seton Hall.
Dr. Petrick is an animal health industry veteran with over 30 years in regulatory affairs.
He was the former head of regulatory affairs at Schering-Plough Animal Health (currently Merck Animal Health).
VP, CMC Supply Chain
A chemical engineer by training, Evangeline has over 25 years of experience in pharmaceutical drug product development and commercial manufacturing.
An expert in drug delivery technologies, Vangie started her career at Alza and then went on to overseeing CMC activities at AcelRx Pharmaceuticals.
